Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers

Abstract

A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispina! space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position.

1 . A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection, and thereafter positioning said human's head below horizontal. 
     
     
         2 . A method for delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer's related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of said human without direct intrathecal injection, and thereafter positioning said human in a Trendelenburg position, for delivery of said golimumab to the brain via the human's vertebral venous system. 
     
     
         3 . A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection. 
     
     
         4 . The method of  claim 1 , wherein said biologic is etanercept. 
     
     
         5 . The method of  claim 1 , wherein said biologic is golimumab. 
     
     
         6 . The method of  claim 1 , wherein said biologic is Gammagard. 
     
     
         7 . The method of  claim 1 , wherein said biologic is bapineuzumab. 
     
     
         8 . The method of  claim 2 , further comprising positioning said human's head below horizontal to facilitate gravity assisted retrograde flow of golimumab to the brain. 
     
     
         9 . The method of  claim 3 , wherein said human has neck pain. 
     
     
         10 . The method of  claim 3 , wherein said human has cervical radiculopathy. 
     
     
         11 . The method of  claim 3 , wherein said human has degenerative disc disease. 
     
     
         12 . The method of  claim 3 , wherein said human has fibromyalgia. 
     
     
         13 . The method of  claim 3 , wherein said human has neuropathic pain. 
     
     
         14 . The method of  claim 3 , wherein said human has sciatica. 
     
     
         15 . The method of  claim 3 , wherein said human has low back pain. 
     
     
         16 . The method of  claim 3 , wherein the human has sciatica, and the biologic is an anti-TNF-alpha therapeutic molecule. 
     
     
         17 . The method of  claim 3 , wherein the human has sciatica, and the biologic is etanercept. 
     
     
         18 . The method of  claim 3 , wherein the biologic is etanercept. 
     
     
         19 . The method of  claim 1 , wherein said administered biologic bypasses the blood-brain barrier to reach the brain. 
     
     
         20 . The method of  claim 3 , wherein said biologic is selected from the group of etanercept, certolizumab pegol, IL-1 Trap, Kineret®, bevacizumab, pegaptanib, ranibizumab, rituximab, Zevalin®, Mylotarg®, Campath®, HumaSpect®, abatacept, cetuximab, panitumumab, pegfilgrastim, filgrastim, erythropoietin, Aranesp®, trastuzumab, Pegasys®, Intron A®, PEG-Intron®, Infergen®, Avonex®, Rebif®, Betaseron®, Actimmune®, Ontak®, Simulect®, Zenapax®, Genkaxin®, recombinant human growth hormone, reteplase, alteplase, tPA (tissue plasminogen activator), urokinase plasminogen activator, streptokinase, urokinase, or immune globulin), Tarceva®, bapineuzumab, Gammagard™, or IVIG.